Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc. Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend

Revolution Medicines Stockholders Vote FOR Proposed Acquisition of EQRx, Inc.

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

REDWOOD CITY, Calif., November 1, 2023 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company

developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ( ISS ) and Glass Lewis & Co.

( Glass Lewis ), have recommended Revolution Medicines stockholders vote FOR the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at

the special meeting of stockholders scheduled for November 8, 2023.

In their respective reports, ISS and Glass Lewis view the proposed transaction

as favorable to Revolution Medicines stockholders. The acquisition will add the significant cash resources held by EQRx and strengthen Revolution Medicines balance sheet, allowing the company to sustain and retain control of its research and

development plans for its RAS(ON) Inhibitor pipeline.

We are pleased that ISS and Glass Lewis support our proposed acquisition of EQRx and the

significant long-term value opportunity this compelling transaction provides to our stockholders, said Mark A. Goldsmith, M.D., Ph.D., Revolution Medicines, chief executive officer and chairman. The addition of approximately

$1.1 billion to our balance sheet will increase our financial strength and enable robust investments to advance the clinical development of RMC-6236, our

RASMULTI(ON) Inhibitor, RMC-6291, our RASG12C(ON) Inhibitor, and

RMC-9805, our RASG12D(ON) Inhibitor. This transaction will also increase our capacity to develop our growing RAS(ON) Inhibitor pipeline in order to deliver

high-impact targeted medicines to an even larger range of patients with RAS-addicted cancers.

also today announced the final exchange ratio for the EQRx acquisition. Each share of common stock of EQRx issued and outstanding immediately prior to the merger will be converted into the right to receive 0.1112 shares of common stock of Revolution

Medicines. If the transaction is completed, Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger (excluding assumed warrants and earn-out

shares). No fractional shares will be issued and EQRx stockholders will receive cash in lieu of any fractional shares as part of the merger consideration, as specified in the merger agreement with EQRx. The transaction is expected to close in

November 2023, subject to satisfaction of customary closing conditions, including approval by both Revolution Medicines and EQRx s stockholders. The company estimates that the acquisition will add approximately $1.1 billion in net

cash proceeds, after estimated post-closing EQRx wind-down and transition costs, or approximately $20 per share of common stock issued in connection with the merger.

Special Meeting of Revolution Medicine Stockholders

The Revolution Medicines Board of Directors recommends Revolution Medicines stockholders vote FOR the issuance of shares in connection with the

proposed transaction with EQRx. Revolution Medicines special meeting of stockholders is scheduled to take place virtually on Wednesday, November 8, 2023 at 8:00 a.m. PT. Only holders of record of Revolution Medicines common stock as of

the close of business on September 26, 2023 are entitled to vote at the special meeting.

Stockholders who have questions or need assistance voting

their shares should contact Revolution Medicines proxy solicitor, Morrow Sodali, LLC at (800) 662-5200 or (203) 658-9400 or by email at rvmd@info.morrowsodali.com.

About Revolution Medicines, Inc.

Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse

oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company s RAS(ON) Inhibitors RMC-6236

(RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company s pipeline include RMC-5127 (KRASG12V), RMC-0708 (KRASQ61H) and RMC-8839 (KRASG13C) which are currently in IND-enabling development, and additional compounds targeting other RAS variants.

Forward Looking Statements

This press release contains

forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and

expectations of management of Revolution Medicines and EQRx in light of historical results and trends, current conditions and potential future developments, and are subject to various risks and uncertainties that could cause actual results to differ

materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as anticipate, expect,

project, intend, believe, may, will, should, plan, could, continue, target, contemplate, estimate,

forecast, guidance, predict, possible, potential, pursue, likely, and words and terms of similar substance used in connection with any discussion of future plans,

actions or events identify forward-looking statements. All statements, other than historical facts, including express or implied statements regarding the proposed transaction; the conversion of equity interests contemplated by the merger agreement;

the issuance of common stock of Revolution Medicines contemplated by the merger agreement; the expected timing of the closing of the proposed transaction; the ability of the parties to complete the proposed transaction considering the various

closing conditions; the expected benefits of the proposed transaction; the competitive ability and position of the combined company; Revolution Medicines development plans and timelines and its ability to advance its portfolio and research and

development pipeline; progression of clinical studies and findings from these studies, including the tolerability and potential efficacy of Revolution Medicines candidates being studied; the potential advantages and effectiveness of Revolution

Medicines clinical and preclinical candidates, including its RAS(ON) Inhibitors; the potential clinical utility of RMC-6236 in patients with non-small cell lung

cancer and pancreatic cancer; the timing and completion of a clinical trial for the combination of RMC-6236 and RMC-6291; whether additional near-term and longer-term

investments will strengthen the clinical advancement of Revolution Medicines RAS(ON) Inhibitors;

Revolution Medicines ability to enable seamless program progression; Revolution Medicines ability to advance its oncology assets and its intention to concentrate development resources

on its three priority RAS-focused assets (RMC-6236, RMC-6291 and RMC-9805) following the

proposed transaction; Revolution Medicines expectation to not advance EQRx s research and development portfolio following closing of the proposed transaction; EQRx s expectation to wind down its programs; and any assumptions

underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Revolution Medicines and EQRx s plans, estimates or expectations described in such

forward-looking statements could include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect Revolution Medicines and EQRx s businesses and

the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the proposed transaction; (iii) the potential failure to receive, on a timely basis or otherwise, the required approvals of the proposed

transaction, including stockholder approvals by both Revolution Medicines stockholders and EQRx s stockholders, and the potential failure to satisfy the other conditions to the consummation of the transaction; (iv) that the proposed

transaction may involve unexpected costs, liabilities or delays; (v) the effect of the announcement, pendency or completion of the proposed transaction on each of Revolution Medicines or EQRx s ability to attract, motivate, retain

and hire key personnel and maintain relationships with customers, distributors, suppliers and others with whom Revolution Medicines or EQRx does business, or on Revolution Medicines or EQRx s operating results and business generally;

(vi) that the proposed transaction may divert management s attention from each of Revolution Medicines and EQRx s ongoing business operations; (vii) the risk of any legal proceedings related to the proposed transaction or

otherwise, or the impact of the proposed transaction thereupon, including resulting expense or delay; (viii) that Revolution Medicines or EQRx may be adversely affected by other economic, business and/or competitive factors; (ix) the

occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement relating to the proposed transaction, including in circumstances which would require Revolution Medicines or EQRx to pay a

termination fee; (x) the risk that restrictions during the pendency of the proposed transaction may impact Revolution Medicines or EQRx s ability to pursue certain business opportunities or strategic transactions; (xi) the risk

that Revolution Medicines or EQRx may be unable to obtain governmental and regulatory approvals required for the proposed transaction, or that required governmental and regulatory approvals may delay the consummation of the proposed transaction or

result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xii) the risk that the anticipated benefits of the proposed transaction

may otherwise not be fully realized or may take longer to realize than expected; (xiii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiv) risks relating to the value of Revolution Medicines

securities to be issued in the proposed transaction; (xv) the risk that integration of the proposed transaction post-closing may not occur as anticipated or the combined company may not be able to achieve the growth prospects expected from the

transaction; (xvi) the effect of the announcement, pendency or completion of the proposed transaction on the market price of the common stock of each of Revolution Medicines and the common stock and publicly traded warrants of EQRx;

(xvii) the implementation of each of Revolution Medicines and EQRx s business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing

and selling potential existing and new products; (xviii) the scope, progress, results and costs of developing Revolution Medicines and EQRx s product

candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Revolution Medicines and

EQRx s pipeline; (xix) the timing and costs involved in obtaining and maintaining regulatory approval for Revolution Medicines and EQRx s current or future product candidates, and any related restrictions, limitations and/or

warnings in the label of an approved product; (xx) the market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Revolution Medicines and EQRx s product candidates and their respective

abilities to compete with therapies and procedures that are rapidly growing and evolving; (xxi) uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of

third-party suppliers and manufacturers; (xxii) the ability of each of Revolution Medicines and EQRx to establish and maintain intellectual property protection for products or avoid or defend claims of infringement; (xxiii) exposure to

inflation, currency rate and interest rate fluctuations and risks associated with doing business locally and internationally, as well as fluctuations in the market price of each of Revolution Medicines and EQRx s traded securities;

(xxiv) risks relating to competition within the industry in which each of Revolution Medicines and EQRx operate; (xxv) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak

of war or hostilities; (xxvi) whether the termination of EQRx s license agreements and/or discovery collaboration agreements may impact its or Revolution Medicines ability to license in additional programs in the future and the risk

of delays or unforeseen costs in terminating such arrangements; (xxvii) risks that restructuring costs and charges may be greater than anticipated or incurred in different periods than anticipated; (xxviii) the risk that EQRx s

restructuring efforts may adversely affect its programs and its ability to recruit and retain skilled and motivated personnel, and may be distracting to employees and management; and (xxix) the risk that EQRx s restructuring or wind-down

efforts may negatively impact its business operations and reputation with or ability to serve counterparties or may take longer to realize than expected, as well as each of Revolution Medicines and EQRx s response to any of the

aforementioned factors. Additional factors that may affect the future results of Revolution Medicines and EQRx are set forth in their respective filings with the U.S. Securities and Exchange Commission (the SEC ), including each of

Revolution Medicines and EQRx s most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC s website at www.sec.gov. See in particular Item 1A of Revolution Medicines Quarterly Report on Form

10-Q for the quarterly period ended June 30, 2023 under the heading Risk Factors, and Item 1A of each of EQRx s Annual Report on Form 10-K for the

fiscal year ended December 31, 2022 and Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2023 and June 30, 2023 under the headings Risk Factors. The risks and

uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Revolution Medicines and EQRx and their respective businesses, including factors that potentially could materially affect their

respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any

forward-looking statements, which speak only as of the date hereof. Readers should also carefully review the risk factors described in other documents that Revolution Medicines and EQRx file from time to time with the SEC. Except as required by law,

each of Revolution Medicines and EQRx assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Additional Information and Where to Find It

In connection with the proposed transaction, Revolution Medicines and EQRx filed with the SEC and mailed or otherwise provided to their respective security

holders a joint proxy statement/prospectus regarding the proposed transaction (as amended or supplemented from time to time, the Joint Proxy Statement/Prospectus ). INVESTORS AND REVOLUTION MEDICINES AND EQRX S RESPECTIVE

SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF REVOLUTION MEDICINES AND EQRX WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY

REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION.

Medicines investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents that Revolution Medicines files with the SEC (when available) from the SEC s website at www.sec.gov and Revolution

Medicines website at ir.revmed.com. In addition, the Joint Proxy Statement/Prospectus and other documents filed by Revolution Medicines with the SEC (when available) may be obtained from Revolution Medicines free of charge by directing a

request to Morrow Sodali LLC at RVMD@info.morrowsodali.com.

EQRx s investors and security holders may obtain a free copy of the Joint Proxy

Statement/Prospectus and other documents that EQRx files with the SEC (when available) from the SEC s website at www.sec.gov and EQRx s website at investors.eqrx.com. In addition, the Joint Proxy Statement/Prospectus and other documents

filed by EQRx with the SEC (when available) may be obtained from EQRx free of charge by directing a request to EQRx s Investor Relations at investors@eqrx.com.

No Offer or Solicitation

This communication is not

intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or

sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities

Act of 1933, as amended.